Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
$34.69
+1.3%
$29.45
$16.54
$38.93
$976.39M0.42195,349 shs494,289 shs
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$2.32
-1.7%
$1.84
$1.07
$4.62
$244.09M0.36657,904 shs186,473 shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$9.35
-2.0%
$8.87
$6.50
$18.98
$990.07M0.8883,406 shs545,958 shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$13.34
-2.3%
$12.26
$9.03
$17.70
$929.57M1.19581,139 shs363,270 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-1.61%+5.30%+22.01%+69.10%+83.60%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
+2.61%+10.13%+33.33%+110.71%+38.01%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
+2.09%+12.29%-5.28%+17.56%-31.81%
Zymeworks Inc. stock logo
ZYME
Zymeworks
+0.66%+6.43%+4.51%+28.50%+47.84%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
1.0692 of 5 stars
3.60.00.00.00.60.80.0
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
2.04 of 5 stars
3.63.00.00.02.40.00.0
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.9444 of 5 stars
4.43.00.00.01.21.70.0
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.1737 of 5 stars
3.51.00.00.01.83.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
3.17
Buy$46.6031.81% Upside
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
3.13
Buy$8.00241.15% Upside
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.89
Moderate Buy$21.29126.93% Upside
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.90
Moderate Buy$21.0055.61% Upside

Current Analyst Ratings Breakdown

Latest PRQR, LENZ, ZYME, and RCUS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$13.00
6/27/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$8.00
6/27/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$8.00
5/20/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/20/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/13/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $9.00
5/9/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$24.00 ➝ $22.00
5/8/2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
5/8/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.00
5/7/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$33.00
5/7/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$29.00 ➝ $26.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/AN/AN/AN/A$7.42 per shareN/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$20.46M12.06N/AN/A$0.91 per share2.58
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$258M3.85N/AN/A$5.30 per share1.77
Zymeworks Inc. stock logo
ZYME
Zymeworks
$93.38M10.07N/AN/A$6.63 per share2.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-$49.77M-$1.77N/AN/AN/AN/A-23.74%-22.65%8/13/2025 (Estimated)
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
-$30.04M-$0.35N/AN/AN/A-157.04%-53.49%-22.07%8/4/2025 (Estimated)
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$283M-$4.19N/AN/AN/A-258.94%-70.58%-32.97%8/4/2025 (Estimated)
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%7/30/2025 (Estimated)

Latest PRQR, LENZ, ZYME, and RCUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.52N/AN/AN/A$17.18 millionN/A
5/8/2025Q1 2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
-$0.09-$0.1082-$0.0182-$0.11$4.90 million$4.89 million
5/8/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million
5/7/2025Q1 2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-$0.55-$0.53+$0.02-$0.53N/AN/A
5/6/2025Q1 2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/AN/AN/AN/AN/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
N/AN/AN/AN/AN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/A
23.09
23.09
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
N/A
4.10
4.10
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.09
5.37
5.37
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
54.32%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
32.65%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
92.89%
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%

Insider Ownership

CompanyInsider Ownership
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
6.90%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
8.40%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
9.60%
Zymeworks Inc. stock logo
ZYME
Zymeworks
1.92%
CompanyEmployeesShares OutstandingFree FloatOptionable
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
11028.15 million26.20 millionN/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
180105.21 million96.38 millionOptionable
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
500105.89 million95.72 millionOptionable
Zymeworks Inc. stock logo
ZYME
Zymeworks
46069.68 million67.56 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LENZ Therapeutics stock logo

LENZ Therapeutics NASDAQ:LENZ

$34.69 +0.43 (+1.26%)
Closing price 04:00 PM Eastern
Extended Trading
$34.82 +0.13 (+0.37%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

ProQR Therapeutics stock logo

ProQR Therapeutics NASDAQ:PRQR

$2.32 -0.04 (-1.69%)
Closing price 04:00 PM Eastern
Extended Trading
$2.42 +0.10 (+4.27%)
As of 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Arcus Biosciences stock logo

Arcus Biosciences NYSE:RCUS

$9.35 -0.19 (-1.99%)
Closing price 03:59 PM Eastern
Extended Trading
$9.24 -0.12 (-1.23%)
As of 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Zymeworks stock logo

Zymeworks NYSE:ZYME

$13.34 -0.32 (-2.34%)
Closing price 04:00 PM Eastern
Extended Trading
$13.34 0.00 (0.00%)
As of 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.